Fig. 1: LNP X formulation potently transfects primary CD4+ T cells in the absence of pre-stimulation.
From: Efficient mRNA delivery to resting T cells to reverse HIV latency
a CD4+ T cells from HIV-negative donors were rested or pre-stimulated with anti-CD3/anti-CD28, then treated with LNPs (similar to the patisiran lipid composition) encapsulating mCherry mRNA for 72 h at the indicated doses. Highest dose of mCherry-LNP X corresponds to 2.5 µg/mL. Transfection efficiency was determined by measuring mCherry expression using flow cytometry. Mean ± SEM, n = 6 donors. b Schematic representation of patisiran-like LNP formulation versus novel LNP formulation X. Mol %, relative molar percentage of indicated lipid in lipid mixture. Created in BioRender: Cevaal, P. (2025) https://BioRender.com/ypaicaz. c Size distribution of patisiran LNP (yellow) versus LNP X (green) encapsulating mCherry mRNA. Lines represent individual LNP batches. d Relative mCherry expression levels in Jurkat T cells treated for 24 h with indicated doses of patisiran LNP (yellow) or LNP X (green) encapsulating mCherry mRNA. MFI, median fluorescent intensity. Mean ± SEM, n = 2. e CD4+ T cells from HIV-negative donors were rested or pre-stimulated with anti-CD3/anti-CD28, then treated with LNP X encapsulating mCherry mRNA for 72 h at the indicated doses. Highest dose of mCherry-LNP X corresponds to 2.5 µg/mL. Transfection efficiency was determined using flow cytometry. Mean ± SEM, n = 6 donors.
